Why the study?
Do different Adriamycin-based combination regimens (FAC, AC, A+COMFP) yield different response rates and survival in patients with previously untreated metastatic breast cancer?
Do different Adriamycin-based combination regimens (FAC, AC, A+COMFP) yield different response rates and survival in patients with previously untreated metastatic breast cancer?
Three Adriamycin-based combination chemotherapy regimens demonstrated similar response rates and overall survival in patients with previously untreated metastatic breast cancer, though FAC was associated with more leukopenia.
No takes yet. Share an insight, caveat, or question.
Similar efficacy among AC, FAC, and A+COMFP in metastatic breast cancer; confirms equivalence and supports toxicity-based regimen selection.
Tranum et al. (1982) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: